Insider Selling: Natera, Inc. (NASDAQ:NTRA) Insider Sells 787 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) insider Daniel Rabinowitz sold 787 shares of the business’s stock in a transaction that occurred on Tuesday, April 23rd. The stock was sold at an average price of $91.38, for a total transaction of $71,916.06. Following the transaction, the insider now owns 205,552 shares of the company’s stock, valued at approximately $18,783,341.76. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Daniel Rabinowitz also recently made the following trade(s):

• On Thursday, February 29th, Daniel Rabinowitz sold 20,526 shares of Natera stock. The stock was sold at an average price of $89.01, for a total transaction of $1,827,019.26.
• On Tuesday, February 27th, Daniel Rabinowitz sold 35,307 shares of Natera stock. The stock was sold at an average price of $75.09, for a total transaction of $2,651,202.63.

Natera Stock Performance

NASDAQ:NTRA opened at $91.50 on Thursday. The company has a quick ratio of 3.96, a current ratio of 4.10 and a debt-to-equity ratio of 0.37. Natera, Inc. has a fifty-two week low of $36.90 and a fifty-two week high of $98.82. The stock has a market cap of $11.05 billion, a PE ratio of -24.29 and a beta of 1.37. The firm’s fifty day simple moving average is $86.85 and its 200-day simple moving average is $66.82.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.09. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. The business had revenue of $311.11 million for the quarter, compared to analysts’ expectations of $300.38 million. Analysts expect that Natera, Inc. will post -2.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Natera

A number of large investors have recently added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC boosted its position in shares of Natera by 28.6% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 720,160 shares of the medical research company’s stock worth $45,111,000 after acquiring an additional 159,993 shares during the last quarter. Cerity Partners LLC lifted its position in Natera by 1,043.3% during the fourth quarter. Cerity Partners LLC now owns 90,423 shares of the medical research company’s stock valued at $5,664,000 after buying an additional 82,514 shares in the last quarter. WCM Investment Management LLC lifted its position in Natera by 101.2% during the fourth quarter. WCM Investment Management LLC now owns 145,996 shares of the medical research company’s stock valued at $9,058,000 after buying an additional 73,419 shares in the last quarter. Aigen Investment Management LP acquired a new position in Natera during the third quarter valued at approximately $223,000. Finally, Sei Investments Co. lifted its position in shares of Natera by 33.4% during the third quarter. Sei Investments Co. now owns 374,004 shares of the medical research company’s stock worth $16,550,000 after purchasing an additional 93,556 shares in the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have commented on NTRA shares. Sanford C. Bernstein upgraded shares of Natera from a “market perform” rating to an “outperform” rating and set a $120.00 price target for the company in a report on Friday, April 5th. The Goldman Sachs Group boosted their price objective on shares of Natera from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Monday, April 15th. StockNews.com downgraded shares of Natera from a “hold” rating to a “sell” rating in a research report on Tuesday. Craig Hallum initiated coverage on shares of Natera in a research report on Monday, April 8th. They set a “buy” rating and a $117.00 price objective for the company. Finally, Stephens restated an “overweight” rating and set a $78.00 price objective on shares of Natera in a research report on Tuesday, January 30th. One research analyst has rated the stock with a sell rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $86.40.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.